Related Experiment Videos
1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents.
Gary M Coppola1, Robert E Damon, J Bruce Eskesen
1Department of Diabetes and Metabolism, Novartis Institutes for Biomedical Research, 100 Technology Square, Cambridge, MA 02139, USA. gary.oppola@pharma.novartis.com
Bioorganic & Medicinal Chemistry Letters
|January 25, 2005
Summary
New compounds were developed to increase HDL cholesterol and Apo A-I levels. Several analogs demonstrated effectiveness comparable or superior to gemfibrozil, offering potential therapeutic benefits.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cardiovascular Research
Background:
- High-density lipoprotein (HDL) cholesterol plays a crucial role in reverse cholesterol transport.
- Apolipoprotein A-I (Apo A-I) is the primary structural and functional component of HDL.
- Dyslipidemia, characterized by abnormal HDL and Apo A-I levels, is a risk factor for cardiovascular disease.
Purpose of the Study:
- To synthesize and evaluate novel 1-hydroxyalkyl-3-phenylthiourea analogs.
- To identify compounds with the potential to elevate HDL and Apo A-I levels.
- To compare the efficacy of these novel compounds with gemfibrozil, a known HDL-raising agent.
Main Methods:
- Synthesis of a series of 1-hydroxyalkyl-3-phenylthiourea derivatives.
- In vitro and/or in vivo assays to measure HDL and Apo A-I levels.
- Comparative analysis of compound efficacy against gemfibrozil.
Main Results:
- Successful preparation of diverse 1-hydroxyalkyl-3-phenylthiourea analogs.
- Identification of specific derivatives (5h, 7j, 7n, and 7o) exhibiting significant HDL- and Apo A-I-elevating properties.
- Demonstration that derivatives 5h, 7j, 7n, and 7o were as effective or superior to gemfibrozil in preclinical evaluations.
Conclusions:
- 1-hydroxyalkyl-3-phenylthiourea analogs represent a promising class of compounds for modulating HDL and Apo A-I levels.
- Derivatives 5h, 7j, 7n, and 7o warrant further investigation as potential therapeutic agents for dyslipidemia.
- These findings contribute to the development of novel strategies for managing cardiovascular risk through lipid modification.